Enzymotec Ltd. to Present New Findings Regarding Positive Effects of INFAT(R) on Chinese Babies Stool and Behavior
June 05 2014 - 3:05PM
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and
marketer of innovative bio-active lipid ingredients, announced
today that results of its clinical trial on INFAT® (structured fat
ingredient for infant nutrition, marketed by Advanced Lipids, a
joint venture of AAK and Enzymotec) will be presented at the
European Society for Pediatric Gastroenterology, Hepatology and
Nutrition (ESPGHAN) Conference on June 9-12, 2014 in Jerusalem,
Israel (to read the full scientific abstract go to:
http://journals.lww.com/jpgn/Documents/ESPGHAN%202014%20Abstracts%20-%20Complete%20abstracts.pdf
Page: 432).
The study is the first to test the effect of a commercial infant
formula containing INFAT® and prebiotics compared to the control
formula containing standard vegetable oil and prebiotics or
breast-fed infants on the well-being of Chinese term infants. The
study was conducted in medical centers across China in
collaboration with Biostime, a leading infant formula company in
China.
The study demonstrated significant benefits of INFAT®, similar
to breastfeeding; it may increase infant comfort by reducing crying
and enhance fat and nutrient absorption during the first weeks of
life compared to the control formula.
"This study further emphasizes the importance of INFAT® as
integral part of the infant early nutrition," said Dr. Fabiana
Bar-Yoseph of Enzymotec R&D infant nutrition. "And our ongoing
commitment to explore the special characteristics and health
benefits of INFAT® on various infant populations."
The INFAT® Advanced Lipids team will participate in the ESPGHAN
conference and will be glad to answer any questions. Please visit
the team at booth R8 for more information.
About INFAT®
INFAT® is sold and marketed by Advanced Lipids, a joint venture
of AAK and Enzymotec, it is a clinically-proven sn-2 palmitate
ingredient that more closely resembles the fat structure and
properties of human milk fat.
About Enzymotec
Enzymotec is a leading global supplier of specialty lipid-based
products and solutions. The Company develops, manufactures and
markets innovative bio-active lipid ingredients, as well as final
products, based on sophisticated processes and technologies. The
Enzymotec Infant Nutrition division develops lipid compositions
that mimic human milk fat to facilitate healthy infant development.
For more information, visit www.enzymotec.com.
About Advanced Lipids AB
Advanced Lipids is a joint venture of AAK and Enzymotec that was
established for the marketing, sale and distribution of INFAT® to
the infant nutrition industry. INFAT® is produced in AAK's state of
the art production facilities in Sweden based on proprietary
enzymatic technology developed by Enzymotec. For more information,
visit www.advancedlipids.com.
Forward Looking Statements
This release may contain forward-looking statements, which
express the current beliefs and expectations of Company management.
Such statements involve a number of known and unknown risks and
uncertainties that could cause our future results, performance or
achievements to differ significantly from the results, performance
or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to
such differences the following risks: we depend on third parties to
obtain raw materials, in particular krill, necessary for the
production of our products; a high proportion of the sales of our
INFAT® product is sold to end users by a single company in China;
we are subject to a degree of customer concentration and our
customers do not enter into long-term purchase commitments with us;
we may be required to pay royalties on sales of our krill products
in North America and Australia; we have in the past, and may in the
future, become subject to litigation regarding intellectual
property rights or other matters; our offering of products as
''medical foods'' in the United States may be challenged by
regulatory authorities; we rely on our Swedish joint venture
partner to manufacture INFAT®, and certain matters related to the
joint venture are the subject of disagreement; we are dependent on
a single facility that houses the majority of our operations; we
may be impacted by delays in manufacturing as we expand our
capacity; we may not be able to expand our production or processing
capabilities or satisfy growing demand; our gross profits may be
adversely affected if we are only able to obtain lower quality
krill meal; our ability to obtain krill may be affected by
conservation regulation or initiatives; our product development
cycle is lengthy and uncertain, and our development or
commercialization efforts for our products may be unsuccessful; we
are subject to significant and increasing government regulations
regarding the sale and marketing of our products; we may not be
able to protect our proprietary technology or prevent its
unauthorized use by third parties; and other factors discussed
under the heading "Risk Factors" in the Company's Form 20-F filed
with the Securities and Exchange Commission on February 13, 2014.
Forward-looking statements in this release are made pursuant to the
safe harbor provisions contained in the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
made only as of the date hereof, and the Company undertakes no
obligation to update or revise the forward-looking statements,
whether as a result of new information, future events or
otherwise.
CONTACT: ICR, LLC
Katie Turner
646-277-1228
-or-
John Mills
310-954-1105
John.Mills@icrinc.com
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024